1. Scrip
  2. >>Business

Dr Michael Rosenblatt joins Merck & Co

Dr Michael Rosenblatt has been named executive vice-president and chief medical officer at Merck & Co. He will report directly to Merck's chairman, president and CEO, Richard Clark, will serve on the company’s executive committee and will oversee the company's global centre for scientific affairs. Dr Rosenblatt has served as dean of Tufts University School of Medicine since 2003. Before that, he was George R Minot Professor of Medicine at Harvard Medical School and chief of the division of bone and mineral metabolism research at Beth Israel Deaconess Medical Center.

Dr Michael Rosenblatt has been named executive vice-president and chief medical officer at Merck & Co. He will report directly to Merck's chairman, president and CEO, Richard Clark, will serve on the company’s executive committee and will oversee the company's global centre for scientific affairs. Dr Rosenblatt has served as dean of Tufts University School of Medicine since 2003. Before that, he was George R Minot Professor of Medicine at Harvard Medical School and chief of the division of bone and mineral metabolism research at Beth Israel Deaconess Medical Center.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

Summit’s Ivonescimab Shows Significance On PFS, But Not Overall Survival

 
• By Joseph Haas

In a study intended to show similar benefit in western patients, PD-1/VEGF-targeting ivonescimab met a progression-free survival endpoint, but missed on OS.

Sanofi Bid For Second COPD Approval Hurt By Mixed Itepekimab Data

 
• By Kevin Grogan

One Phase III trial hits but a second study misses by a mile.

Astellas Gets CLDN.18.2-Targeted ADC From China’s Evopoint

 
• By Joseph Haas

Astellas will pay $130m up front for near-global rights to a Phase I/II antibody-drug conjugate that will add to its portfolio of CLDN.18.2-targeted drugs, including Vyloy.

All Over For iTeos But Applause For Plan To Return Cash Fast

 
• By Kevin Grogan

The company has moved quickly to wind down operations after its anti-TIGIT pact with GSK collapsed.

More from Scrip

Quotables: Pharma Leaders On The Month’s Hot Topics

 
• By Anabel Costa-Ferreira

The highlights of recent comments and insights from industry executives on the key issues covered in Scrip.

In Brief: Neurocrine Details New Data For Schizophrenia Drug Moving To Phase III

 
• By Sushmita Panda

Neurocrine reports new details of positive Phase II results in schizophrenia and a favorable safety and cardiovascular profile for its first-in-class oral M4 agonist, now moving to Phase III trials.

Astellas Gets CLDN.18.2-Targeted ADC From China’s Evopoint

 
• By Joseph Haas

Astellas will pay $130m up front for near-global rights to a Phase I/II antibody-drug conjugate that will add to its portfolio of CLDN.18.2-targeted drugs, including Vyloy.